Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent ...

Importance: Disease models for atopic dermatitis (AD) have primarily focused on understanding ... Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...